China’s surging biotech sector represents both competition and lifeline for the US
As Chinese companies push beyond “me-too” drugs and the country lays out a new five-year plan targeting a $522 billion–strong biotech industry by 2030, experts say more predictable funding and regulation could help the U.S. maintain its edge.
China’s surging biotech sector represents both competition and lifeline for the US Read More »
